Major Extremity Trauma Research Consortium
Trial Pipeline
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
NCT06337292
Evaluation of the Diagnostic and Therapeutic Value of Tissue Ultrafiltration in Patients at Risk of Acute Compartment Syndrome (ACS)
NCT05889559
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
NCT04789044
PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation
NCT05699174
Multicenter Trial Evaluating the Safety and Efficacy of Autologous Volar Fibroblast Injection Into the Terminal Limb of Amputees.
NCT04839497
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
NCT07006675
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
NCT04678154
Effects of Early Weight Bearing on Rehabilitation Outcomes in Patients With Traumatic Ankle and Tibial Plateau Fractures
NCT04028414
Rehabilitation Enhanced by Partial Arterial Inflow Restrictions
NCT02746458
Serum-Protein-Based Indices for the Progression of Fracture Healing and Nonunion
NCT05143476
Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA
NCT04597008
Early Advanced Weight Bearing for Peri-articular Knee and Pilon Injuries
NCT03562364
Randomized Trial to Assess PO Versus IV Antibiotics
NCT01714596
Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)
NCT01789216
Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery
NCT01798810
Outcomes Following Severe Distal Tibia, Ankle and/or Foot Trauma: Comparison of Limb Salvage Versus Transtibial Amputation Protocol
NCT01606501
Assessment of Severe Extremity Wound Bioburden at the Time of Definitive Wound Closure or Coverage
NCT01496014
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 29 |
| Phase 3 | 33 |
What the Pipeline for Major Extremity Trauma Research Consortium Shows
According to the ClinicalTrials.gov registry, Major Extremity Trauma Research Consortium is linked to 71 US clinical trials across every stage of research activity. Of those, 61 studies are currently recruiting — about 86% of the sponsor's indexed portfolio — and 8 are already marked complete, representing roughly 11% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Major Extremity Trauma Research Consortium reports 33 late-stage studies (Phase 3 and Phase 4 combined) and 29 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Major Extremity Trauma Research Consortium is Post Operative Surgical Site Infection with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.